A randomised vaccine field trial in Kenya demonstrates protection against wildebeest-associated malignant catarrhal fever in cattle

A randomised vaccine field trial in Kenya demonstrates protection against wildebeest-associated malignant catarrhal fever in cattle

Highlights•Wildebeest-associated malignant catarrhal fever is a fatal disease of cattle. •Seasonal disease caused by alcelaphine herpesvirus-1 with incidence up to 10% •Randomised placebo trial for the efficacy of alcelaphine herpesvirus-1 C500 vaccine. •The vaccine efficacy for controlling malignan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2019-09, Vol.37 (40), p.5946-5953
Hauptverfasser: Cook, Elizabeth, Russell, George, Grant, Dawn, Mutisya, Christine, Omoto, Lazarus, Dobson, Elizabeth, Lankester, Felix, Nene, Vishvanath
Format: Artikel
Sprache:eng
Schlagworte:
Alcelaphine herpesvirus 1
Allergy and Immunology
Animal welfare
Cattle
Data collection
Disease
Enzyme-linked immunosorbent assay
Fever
Histopathology
Infections
Livestock
Malignant catarrhal fever
Pathology
Predation
Randomization
Vaccination
Vaccine efficacy
Vaccine field trial
Vaccines
Wildebeest
Wildlife conservation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights•Wildebeest-associated malignant catarrhal fever is a fatal disease of cattle. •Seasonal disease caused by alcelaphine herpesvirus-1 with incidence up to 10% •Randomised placebo trial for the efficacy of alcelaphine herpesvirus-1 C500 vaccine. •The vaccine efficacy for controlling malignant catarrhal fever in cattle over 80% •Safe and effective novel method for controlling malignant catarrhal fever in cattle.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.08.040